Patents Assigned to NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
-
Publication number: 20180265866Abstract: The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.Type: ApplicationFiled: September 15, 2016Publication date: September 20, 2018Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Yukiko ENYA, Yuichiro TONE, Shin'ichi TAKEDA, Yoshitsugu AOKI
-
Publication number: 20180186887Abstract: The present invention provides a novel therapeutic agent for mental illness. The therapeutic agent for mental illness comprises an IL-6 inhibitor as an active ingredient.Type: ApplicationFiled: June 3, 2016Publication date: July 5, 2018Applicants: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Hiroshi KUNUGI, Chisato WAKABAYASHI
-
Publication number: 20180179538Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.Type: ApplicationFiled: February 22, 2018Publication date: June 28, 2018Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Tatsushi Wakayama, Haruna Seo, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
-
Publication number: 20180169052Abstract: An agent for improving brain function and agent for preventing or treating cognitive impairment, which comprises: 5 to 50 parts by weight of a protein; 5 to 80 parts by weight of a medium-chain fatty acid triglyceride as a lipid; and 1 to 50 parts by weight of a carbohydrate, per 100 parts by weight.Type: ApplicationFiled: July 23, 2015Publication date: June 21, 2018Applicants: THE FOOD SCIENCE INSTITUTE FOUNDATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Hiroshi KUNUGI, Miho OTA, Junko MATSUO, Yoshitatsu ICHIHARA
-
Patent number: 9988629Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.Type: GrantFiled: March 11, 2015Date of Patent: June 5, 2018Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Tatsushi Wakayama, Haruna Seo, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
-
Publication number: 20180149573Abstract: According to the present invention, the therapeutic effect of an IL-6 inhibitor on MS was found to be predictable by using as indicators the amount of plasmablasts and/or the indicator of change in immature plasmablasts (amount of immature plasmablasts or amount of follicular helper T cells) in MS patients with a large amount of plasmablasts. Furthermore, IL-6 inhibitors were found to be effective against MS in which plasmablasts occur at high levels and in which the indicator of change in immature plasmablasts is high. The present invention provides methods for selecting MS cases for which treatment with an IL-6 inhibitor is effective, and also provides an effective therapeutic method for patients with MS in which plasmablast occur at high levels and in which the indicator of change in immature plasmablasts is high.Type: ApplicationFiled: May 19, 2016Publication date: May 31, 2018Applicants: National Center of Neurology and Psychiatry, Chugai Seiyaku Kabushiki KaishaInventors: Takashi Yamamura, Masakazu Nakamura
-
Publication number: 20180140655Abstract: An agent uses at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof as an active ingredient. The present invention also provides an agent for improving a neuropsychologic function, which contains at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof as an active ingredient. The present invention also provides an agent for changing expression of a transporter such as SLC23A2, which contains at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof, and an agent for controlling blood concentration of a cytokine such as IP-10, which contains at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof, as well as an expression analysis method for detecting improvement or degradation of a neuropsychologic function, and a kit for detecting improvement or degradation of a neuropsychologic function.Type: ApplicationFiled: January 22, 2018Publication date: May 24, 2018Applicants: THE UNIVERSITY OF TOKYO, KYUSHU UNIVERSITY, NAT'L UNIVERSITY CORPORATION, NH FOODS LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Tatsuhiro Hisatsune, Mamoru Totsuka, Hideo Satsu, Jun Kaneko, Yoshinori Katakura, Mikako Sato, Takashi Matsumoto, Fumiki Morimatsu, Etsuko Imabayashi, Hiroshi Matsuda
-
Publication number: 20180142245Abstract: The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.Type: ApplicationFiled: January 12, 2018Publication date: May 24, 2018Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Haruna SEO, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Publication number: 20180100177Abstract: A marker for determining a mental disease is provided. The marker can be used in an objective diagnosis of such a mental disease. The marker contains one or more enterobacteria of Bifidobacterium, Lactobacillus, Lactobacillus brevis, Lactobacillus reuteri subgroup, Lactobacillus sakei subgroup, Atopobium cluster, Bacteroides fragilis group, Enterococcus, Clostridium coccoides group, Clostridium leptum subgroup, Staphylococcus, Clostridium perfringens, and Enterobacteriaceae.Type: ApplicationFiled: April 15, 2016Publication date: April 12, 2018Applicants: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, KABUSHIKI KAISHA YAKULT HONSHAInventors: Hiroshi KUNUGI, Emiko AIZAWA, Hirokazu TSUJI
-
Publication number: 20180057493Abstract: A morphinan derivative represented by the following general formula (I): (wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc., R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group, Y binds to a carbon atom as a ring-constituting atom of R2, R3, R4, and R5 represent hydrogen; hydroxy, etc., R6a and R6b represent hydrogen, etc., R7 and R8 represent hydrogen, etc., R9 and R10, which are the same or different, represent hydrogen, etc., X represents O or CH2, and Y represents C(?O)), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.Type: ApplicationFiled: March 17, 2016Publication date: March 1, 2018Applicants: UNIVERSITY OF TSUKUBA, SCHOOL JURIDICAL PERSON KITASATO INSTITUTE, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi NAGASE, Hideaki FUJII, Akiyoshi SAITOH, Eriko NAKATA, Masaaki HIROSE, Isao OOI, Kohei HAYASHIDA
-
Publication number: 20180044675Abstract: Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.Type: ApplicationFiled: August 15, 2017Publication date: February 15, 2018Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Yuuichirou TONE, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Patent number: 9890381Abstract: The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.Type: GrantFiled: October 31, 2016Date of Patent: February 13, 2018Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki Watanabe, Haruna Seo, Shin'ichi Takeda, Tetsuya Nagata
-
Patent number: 9848811Abstract: Provided is a cognitive function testing system capable of efficiently and objectively measuring cognitive functions related to, for example, ADHD and easily collecting detailed data. In addition, a cognitive function estimation system is provided to enable estimating and determining the probability of an individual having a disorder such as ADHD after the cognitive functions related to, for example, ADHD have been efficiently and objectively measured. In contrast to the conventional Stroop interference test that uses paper, one problem is displayed on one screen, and not only the correctness result of the problem for the test subject, but also coordinate information for when the test subject responds by manipulating a touch panel display, are recorded in a problem answer table. Furthermore, an estimation calculation based on a learning algorithm can be used to estimate the degree of cognitive function of the test subject.Type: GrantFiled: January 22, 2013Date of Patent: December 26, 2017Assignee: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Akira Yasumura, Masumi Inagaki
-
Patent number: 9840706Abstract: Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.Type: GrantFiled: June 16, 2015Date of Patent: December 12, 2017Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki Watanabe, Yuuichirou Tone, Shin'ichi Takeda, Tetsuya Nagata
-
Publication number: 20170320903Abstract: The present invention provides a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.Type: ApplicationFiled: June 12, 2017Publication date: November 9, 2017Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Publication number: 20170204410Abstract: Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.Type: ApplicationFiled: June 16, 2015Publication date: July 20, 2017Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Yuuichirou TONE, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Patent number: 9708361Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: GrantFiled: February 6, 2015Date of Patent: July 18, 2017Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
-
Publication number: 20170172936Abstract: An object of the present invention is to develop and provide a method for conveniently introducing a nucleic acid, a peptide, and/or a low-molecular-weight compound into an empty capsid with viral early infection activities kept. The present invention provides a method for producing a drug delivery particle, comprising the steps of: mixing an empty capsid or an empty particle with a drug including a nucleic acid, a peptide, and/or a low-molecular-weight compound in a solution comprising 0.1 to 20% of a surfactant; and keeping the obtained mixed solution at ?5 to 50° C. to introduce the drug into the empty capsid or the empty particle.Type: ApplicationFiled: February 28, 2017Publication date: June 22, 2017Applicant: National Center of Neurology and PsychiatryInventors: Takashi Okada, Shin'ichi Takeda, Hiromi Kinoh
-
Publication number: 20170165314Abstract: An anti-aging agent derived from a natural product is provided. The agent uses at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof as an active ingredient. The present invention also provides an agent for improving a neuropsychologic function, which contains at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof as an active ingredient.Type: ApplicationFiled: March 4, 2015Publication date: June 15, 2017Applicants: THE UNIVERSITY OF TOKYO, KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, NH FOODS LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Tatsuhiro Hisatsune, Mamoru Totsuka, Hideo Satsu, Jun Kaneko, Yoshinori Katakura, Mikako Sato, Takashi Matsumoto, Fumiki Morimatsu, Etsuko Imabayashi, Hiroshi Matsuda
-
Patent number: 9610354Abstract: An object of the present invention is to develop and provide a method for conveniently introducing a nucleic acid, a peptide, and/or a low-molecular-weight compound into an empty capsid with viral early infection activities kept. The present invention provides a method for producing a drug delivery particle, comprising the steps of: mixing an empty capsid or an empty particle with a drug including a nucleic acid, a peptide, and/or a low-molecular-weight compound in a solution comprising 0.1 to 20% of a surfactant; and keeping the obtained mixed solution at ?5 to 50° C. to introduce the drug into the empty capsid or the empty particle.Type: GrantFiled: April 16, 2012Date of Patent: April 4, 2017Assignee: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Takashi Okada, Shin'ichi Takeda, Hiromi Kinoh